Biomarker value and pitfalls of serum S100B in the follow-up of high-risk melanoma patients

Christoffer Gebhardt; Ramtin Lichtenberger; Jochen Utikal

doi:10.1111/ddg.12727

Biomarker value and pitfalls of serum S100B in the follow-up of high-risk melanoma patients

Standard

Biomarker value and pitfalls of serum S100B in the follow-up of high-risk melanoma patients. / Gebhardt, Christoffer; Lichtenberger, Ramtin; Utikal, Jochen.

in: J DTSCH DERMATOL GES, Jahrgang 14, Nr. 2, 02.2016, S. 158-64.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Gebhardt, C, Lichtenberger, R & Utikal, J 2016, 'Biomarker value and pitfalls of serum S100B in the follow-up of high-risk melanoma patients', J DTSCH DERMATOL GES, Jg. 14, Nr. 2, S. 158-64. https://doi.org/10.1111/ddg.12727

APA

Gebhardt, C., Lichtenberger, R., & Utikal, J. (2016). Biomarker value and pitfalls of serum S100B in the follow-up of high-risk melanoma patients. J DTSCH DERMATOL GES, 14(2), 158-64. https://doi.org/10.1111/ddg.12727

Vancouver

Gebhardt C, Lichtenberger R, Utikal J. Biomarker value and pitfalls of serum S100B in the follow-up of high-risk melanoma patients. J DTSCH DERMATOL GES. 2016 Feb;14(2):158-64. https://doi.org/10.1111/ddg.12727

Bibtex

@article{ed8b4f54a9804bdc8f405b663ccdaaa8,

title = "Biomarker value and pitfalls of serum S100B in the follow-up of high-risk melanoma patients",

abstract = "BACKGROUND AND OBJECTIVES: Serum levels of S100B are standard in monitoring advanced malignant melanoma patients in order to discriminate progressive from non-progressive disease. False-positive results lead to distress among patients and increase the amount of cost-intensive diagnostics. We therefore analyzed reported comorbid diseases as putative sources of excessive S100B release.PATIENTS AND METHODS: Here, we report a single-center experience on serum S100B levels in 2,664 blood samples from 1,113 stage IB to IV melanoma patients (AJCC) who presented for follow-up examinations over a period of 24 months.RESULTS: Overall, 295 (11%) of patients developed disease progression. In patients with a high tumor load, the rate of false-negative results was 30/185 (16%). The rate of false-positive results was 247/2369 (12%). One hundred and six false-positive results (69%) compared to 46 true-positive results (31%) were found in patients with cardiovascular diseases such as arrhythmia (50/32) or previous myocardial infarction (22/14). Moreover, obesity (85/14), liver cirrhosis (31/10), migraine (18/2), chronic kidney disease (13/2), and previous stroke (11/1) were found to be associated with false-positive S100B levels.CONCLUSIONS: Serum S100B is a useful quantitative biomarker in routine follow-up of high-risk melanoma patients. While false-negative results are frequent in patients with low tumor load, false-positive results are associated with several comorbid diseases and warrant careful reevaluation.",

keywords = "Adolescent, Adult, Aged, Aged, 80 and over, Biomarkers, Tumor, Diagnostic Errors, False Negative Reactions, False Positive Reactions, Female, Germany, Humans, Longitudinal Studies, Male, Melanoma, Middle Aged, Neoplasm Proteins, Prevalence, Reproducibility of Results, Risk Assessment, S100 Calcium Binding Protein beta Subunit, Sensitivity and Specificity, Skin Neoplasms, Young Adult, Journal Article, Research Support, Non-U.S. Gov't",

author = "Christoffer Gebhardt and Ramtin Lichtenberger and Jochen Utikal",

note = "{\textcopyright} 2016 Deutsche Dermatologische Gesellschaft (DDG). Published by John Wiley & Sons Ltd.",

year = "2016",

month = feb,

doi = "10.1111/ddg.12727",

language = "English",

volume = "14",

pages = "158--64",

journal = "J DTSCH DERMATOL GES",

issn = "1610-0379",

publisher = "Wiley-Blackwell",

number = "2",

}

RIS

TY - JOUR

T1 - Biomarker value and pitfalls of serum S100B in the follow-up of high-risk melanoma patients

AU - Gebhardt, Christoffer

AU - Lichtenberger, Ramtin

AU - Utikal, Jochen

PY - 2016/2

Y1 - 2016/2

N2 - BACKGROUND AND OBJECTIVES: Serum levels of S100B are standard in monitoring advanced malignant melanoma patients in order to discriminate progressive from non-progressive disease. False-positive results lead to distress among patients and increase the amount of cost-intensive diagnostics. We therefore analyzed reported comorbid diseases as putative sources of excessive S100B release.PATIENTS AND METHODS: Here, we report a single-center experience on serum S100B levels in 2,664 blood samples from 1,113 stage IB to IV melanoma patients (AJCC) who presented for follow-up examinations over a period of 24 months.RESULTS: Overall, 295 (11%) of patients developed disease progression. In patients with a high tumor load, the rate of false-negative results was 30/185 (16%). The rate of false-positive results was 247/2369 (12%). One hundred and six false-positive results (69%) compared to 46 true-positive results (31%) were found in patients with cardiovascular diseases such as arrhythmia (50/32) or previous myocardial infarction (22/14). Moreover, obesity (85/14), liver cirrhosis (31/10), migraine (18/2), chronic kidney disease (13/2), and previous stroke (11/1) were found to be associated with false-positive S100B levels.CONCLUSIONS: Serum S100B is a useful quantitative biomarker in routine follow-up of high-risk melanoma patients. While false-negative results are frequent in patients with low tumor load, false-positive results are associated with several comorbid diseases and warrant careful reevaluation.

AB - BACKGROUND AND OBJECTIVES: Serum levels of S100B are standard in monitoring advanced malignant melanoma patients in order to discriminate progressive from non-progressive disease. False-positive results lead to distress among patients and increase the amount of cost-intensive diagnostics. We therefore analyzed reported comorbid diseases as putative sources of excessive S100B release.PATIENTS AND METHODS: Here, we report a single-center experience on serum S100B levels in 2,664 blood samples from 1,113 stage IB to IV melanoma patients (AJCC) who presented for follow-up examinations over a period of 24 months.RESULTS: Overall, 295 (11%) of patients developed disease progression. In patients with a high tumor load, the rate of false-negative results was 30/185 (16%). The rate of false-positive results was 247/2369 (12%). One hundred and six false-positive results (69%) compared to 46 true-positive results (31%) were found in patients with cardiovascular diseases such as arrhythmia (50/32) or previous myocardial infarction (22/14). Moreover, obesity (85/14), liver cirrhosis (31/10), migraine (18/2), chronic kidney disease (13/2), and previous stroke (11/1) were found to be associated with false-positive S100B levels.CONCLUSIONS: Serum S100B is a useful quantitative biomarker in routine follow-up of high-risk melanoma patients. While false-negative results are frequent in patients with low tumor load, false-positive results are associated with several comorbid diseases and warrant careful reevaluation.

KW - Adolescent

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Biomarkers, Tumor

KW - Diagnostic Errors

KW - False Negative Reactions

KW - False Positive Reactions

KW - Female

KW - Germany

KW - Humans

KW - Longitudinal Studies

KW - Male

KW - Melanoma

KW - Middle Aged

KW - Neoplasm Proteins

KW - Prevalence

KW - Reproducibility of Results

KW - Risk Assessment

KW - S100 Calcium Binding Protein beta Subunit

KW - Sensitivity and Specificity

KW - Skin Neoplasms

KW - Young Adult

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

U2 - 10.1111/ddg.12727

DO - 10.1111/ddg.12727

M3 - SCORING: Journal article

C2 - 26819111

VL - 14

SP - 158

EP - 164

JO - J DTSCH DERMATOL GES

JF - J DTSCH DERMATOL GES

SN - 1610-0379

IS - 2

ER -